Search

Your search keyword '"Kim, Min Kyoung"' showing total 15 results
Start Over Author "Kim, Min Kyoung" Journal cancer research and treatment
15 results on '"Kim, Min Kyoung"'

1. Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials

Author

Kim, Youjin, primary, Keam, Bhumsuk, additional, Kang, Eun Joo, additional, Kim, Jin-Soo, additional, Kim, Hye Ryun, additional, Lee, Keun-Wook, additional, Kwon, Jung Hye, additional, Lee, Kyoung Eun, additional, Yang, Yaewon, additional, Choi, Yoon Hee, additional, Kim, Min Kyoung, additional, Ji, Jun Ho, additional, Yun, Tak, additional, Choi, Moon Young, additional, Lee, Ki Hyeong, additional, Kim, Sung-Bae, additional, and Ahn, Myung-Ju, additional

Published
2024
Full Text
View/download PDF

2. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts

Author

Yi, Jun Ho, primary, Jeong, Seong Hyun, additional, Kim, Seok Jin, additional, Yoon, Dok Hyun, additional, Kang, Hye Jin, additional, Koh, Youngil, additional, Kim, Jin Seok, additional, Lee, Won-Sik, additional, Yang, Deok-Hwan, additional, Do, Young Rok, additional, Kim, Min Kyoung, additional, Yoo, Kwai Han, additional, Choi, Yoon Seok, additional, Yun, Whan Jung, additional, Park, Yong, additional, Jo, Jae-Cheol, additional, Eom, Hyeon-Seok, additional, Kwak, Jae-Yong, additional, Shin, Ho-Jin, additional, Park, Byeong Bae, additional, Yi, Seong Yoon, additional, Kwon, Ji-Hyun, additional, Oh, Sung Yong, additional, Kim, Hyo Jung, additional, Sohn, Byeong Seok, additional, Won, Jong Ho, additional, Hong, Dae-Sik, additional, Lee, Ho-Sup, additional, Lee, Gyeong-Won, additional, Suh, Cheolwon, additional, and Kim, Won Seog, additional

Published
2023
Full Text
View/download PDF

3. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)

Author

Cho, Hyungwoo, primary, Yoon, Dok Hyun, additional, Shin, Dong-Yeop, additional, Koh, Youngil, additional, Yoon, Sung-Soo, additional, Kim, Seok Jin, additional, Do, Young Rok, additional, Lee, Gyeong-Won, additional, Kwak, Jae-Yong, additional, Park, Yong, additional, Kim, Min Kyoung, additional, Kang, Hye Jin, additional, Yi, Jun Ho, additional, Yoo, Kwai Han, additional, Lee, Won Sik, additional, Park, Byeong Bae, additional, Jo, Jae-Cheol, additional, Eom, Hyeon-Seok, additional, Kim, Hyo Jung, additional, Jeong, Seong Hyun, additional, Won, Young-Woong, additional, Sohn, Byeong Seok, additional, Kwon, Ji-Hyun, additional, Suh, Cheolwon, additional, and Kim, Won Seog, additional

Published
2023
Full Text
View/download PDF

4. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study

Author

Jeong, Seong Hyun, primary, Kim, Seok Jin, additional, Yoon, Dok Hyun, additional, Park, Yong, additional, Kang, Hye Jin, additional, Koh, Youngil, additional, Lee, Gyeong-Won, additional, Lee, Won-Sik, additional, Yang, Deok-Hwan, additional, Do, Young Rok, additional, Kim, Min Kyoung, additional, Yoo, Kwai Han, additional, Choi, Yoon Seok, additional, Yun, Hwan Jung, additional, Yi, Jun Ho, additional, Jo, Jae-Cheol, additional, Eom, Hyeon-Seok, additional, Kwak, Jae-Yong, additional, Shin, Ho-Jin, additional, Park, Byeong Bae, additional, Hyun, Shin Young, additional, Yi, Seong Yoon, additional, Kwon, Ji-Hyun, additional, Oh, Sung Yong, additional, Kim, Hyo Jung, additional, Sohn, Byeong Seok, additional, Won, Jong Ho, additional, Kim, Se-Hyung, additional, Lee, Ho-Sup, additional, Suh, Cheolwon, additional, and Kim, Won Seog, additional

Published
2022
Full Text
View/download PDF

5. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)

Author

Lee, Yun-Gyoo, primary, Kang, Eun Joo, additional, Keam, Bhumsuk, additional, Choi, Jin-Hyuk, additional, Kim, Jin-Soo, additional, Park, Keon Uk, additional, Lee, Kyoung Eun, additional, Kim, Hyo Jung, additional, Lee, Keun-Wook, additional, Kim, Min Kyoung, additional, Ahn, Hee Kyung, additional, Shin, Seong Hoon, additional, Kim, Hye Ryun, additional, Kim, Sung-Bae, additional, and Yun, Hwan Jung, additional

Published
2022
Full Text
View/download PDF

6. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma

Author

Lim, Sun Min, primary, Cho, Sang Hee, additional, Hwang, In Gyu, additional, Choi, Jae Woo, additional, Chang, Hyun, additional, Ahn, Myung-Ju, additional, Park, Keon Uk, additional, Kim, Ji-Won, additional, Ko, Yoon Ho, additional, Ahn, Hee Kyung, additional, Cho, Byoung Chul, additional, Nam, Byung-Ho, additional, Chun, Sang Hoon, additional, Hong, Ji Hyung, additional, Kwon, Jung Hye, additional, Choi, Jong Gwon, additional, Kang, Eun Joo, additional, Yun, Tak, additional, Lee, Keun-Wook, additional, Kim, Joo-Hang, additional, Kim, Jin Soo, additional, Lee, Hyun Woo, additional, Kim, Min Kyoung, additional, Jung, Dongmin, additional, Kim, Ji Eun, additional, Keam, Bhumsuk, additional, Yun, Hwan Jung, additional, Kim, Sangwoo, additional, and Kim, Hye Ryun, additional

Published
2019
Full Text
View/download PDF

7. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Author

Kim, Miso, primary, Keam, Bhumsuk, additional, Kim, Tae-Min, additional, Kim, Hoon-Gu, additional, Kim, Jin-Soo, additional, Lee, Sung Sook, additional, Shin, Seong Hoon, additional, Kim, Min Kyoung, additional, Park, Keon Uk, additional, Kim, Dong-Wan, additional, Yun, Hwan Jung, additional, Lee, Jong Seok, additional, and Heo, Dae Seog, additional

Published
2017
Full Text
View/download PDF

8. Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

Author

Hong, Junshik, primary, Kim, Seok Jin, additional, Ahn, Jae-Sook, additional, Song, Moo Kon, additional, Kim, Yu Ri, additional, Lee, Ho Sup, additional, Yhim, Ho-Young, additional, Yoon, Dok Hyun, additional, Kim, Min Kyoung, additional, Oh, Sung Yong, additional, Park, Yong, additional, Mun, Yeung-Chul, additional, Do, Young Rok, additional, Ryoo, Hun-Mo, additional, Lee, Je-Jung, additional, Lee, Jae Hoon, additional, Kim, Won Seog, additional, and Suh, Cheolwon, additional

Published
2014
Full Text
View/download PDF

10. Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients

Author

Kim, Min Kyoung, primary, Kim, Sung-Bae, additional, Ahn, Jin Hee, additional, Lee, Soon Im, additional, Ahn, Sei-Hyun, additional, Son, Byung Ho, additional, Gong, Gyungyub, additional, Kim, Hak-Hee, additional, Lee, Jung-Shin, additional, Kang, Yoon-Koo, additional, and Kim, Woo Kun, additional

Published
2006
Full Text
View/download PDF

14. Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.

Author

Kim YR, Kim JS, Kim WS, Eom HS, Yang DH, Bae SH, Kim HJ, Lee JH, Oh SJ, Yoon SS, Kwak JY, Choi CW, Kim MK, Oh SY, Kang HJ, Nam SH, Shim H, Park JS, Mun YC, and Suh C

Subjects
Humans, Male, Rituximab therapeutic use, Vincristine, Cyclophosphamide, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols adverse effects, Treatment Outcome, Prednisolone adverse effects, Lymphoma, Large B-Cell, Diffuse pathology
Abstract

Purpose: This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL)., Materials and Methods: Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy., Results: Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016)., Conclusion: Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781.

Published
2023
Full Text
View/download PDF

15. Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.

Author

Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, and Suh C

Abstract

Purpose: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI)., Materials and Methods: Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study., Results: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate., Conclusion: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results